SolAeroMed, Inc.
🇨🇦Canada
- Country
- 🇨🇦Canada
- Ownership
- Holding
- Established
- 2011-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.solaeromed.com
Clinical Trials
5
Active:0
Completed:2
Trial Phases
2 Phases
Phase 1:1
Phase 2:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 2
4 (80.0%)Phase 1
1 (20.0%)Safety, Tolerability and Efficacy of S-1226 in Post-COVID-19 Subjects With Persistent Respiratory Symptoms.
Phase 2
- Conditions
- COVID-19 Respiratory InfectionPost Acute COVID-19 SyndromeLong COVID
- Interventions
- Drug: S-1226 (8%)Other: Placebo
- First Posted Date
- 2021-07-02
- Last Posted Date
- 2021-08-23
- Lead Sponsor
- SolAeroMed Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT04949386
Safety, Tolerability and Efficacy Of S-1226 in Moderate Severity Covid-19 Bronchiolitis/Pneumonia
- First Posted Date
- 2021-02-04
- Last Posted Date
- 2021-08-23
- Lead Sponsor
- SolAeroMed Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT04738136
- Locations
- 🇨🇦
Alberta Lung Function, Calgary, Alberta, Canada
Safety, Tolerability and Efficacy of S-1226 in Cystic Fibrosis and Non CF Bronchiectasis
- First Posted Date
- 2019-04-04
- Last Posted Date
- 2021-06-16
- Lead Sponsor
- SolAeroMed Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT03903913
- Locations
- 🇨🇦
Adult Cystic Fibrosis Clinic at the Foothills Hospital, Calgary, Alberta, Canada
🇨🇦Pediatric Cystic Fibrosis Clinic at Alberta Children's Hospital, Calgary, Alberta, Canada
🇨🇦Alberta Lung Function, Calgary, Alberta, Canada
Phase1, Placebo-Controlled, Randomized, Double-blind, Single-ascending Dose Study in Healthy Subjects.
Phase 1
Completed
- Conditions
- Asthma
- Interventions
- Drug: Saline (for 12%)Drug: Saline (for 4%)Drug: Saline (for 8%)Drug: S1226 (4%)Drug: S1226(8%)Drug: S1226(12%)
- First Posted Date
- 2015-11-30
- Last Posted Date
- 2015-11-30
- Lead Sponsor
- SolAeroMed Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT02616770
Single Dose Study to Evaluate the Safety, and Efficacy of S-1226 (8%) in Subjects With Mild Atopic Asthma
Phase 2
Completed
- Conditions
- Asthma
- Interventions
- Drug: S1226(8%)Drug: Placebo
- First Posted Date
- 2015-01-08
- Last Posted Date
- 2019-02-18
- Lead Sponsor
- SolAeroMed Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT02334553
- Locations
- 🇨🇦
Respiratory Clinical Trials Centre, University of Calgary, Calgary, Alberta, Canada
News
No news found